TNFSF11 and neoplasm: Interestingly, since the RANK/RANKL signal might also enhance the anti-tumor immune responses in patients treated with ICIs in several cancer species including melanoma [59,60], RANKL might be one of the best stromal targets in patients treated with ICIs in the future.